The University of Minnesota is conducting clinical trials for an innovative treatment that utilizes CRISPR technology to combat metastatic gastrointestinal epithelial cancer. The treatment is based on research conducted by Branden Moriarity, PhD, Beau Webber, PhD, and R. Scott McIvor, PhD, of the University of Minnesota Medical School and the Masonic Cancer Center, University of Minnesota. Researchers will use a small piece of a patient’s tumor to create gene-edited white blood cells that may be effective in combating the patient’s cancer. The Masonic Cancer Center is a Consortium member center. Read more on the Masonic Cancer Center website.
Wednesday, October 21, 2020